J07BN04 - Covid-19, Protein Subunit |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the protein subunit Covid-19 vaccine, no porphyrinogenic effects are expected.
Chemical description
Protein subunit vaccine.
Therapeutic characteristics
Indicated for preventing coronavirus disease 2019 (COVID-19) in individuals aged 12 years and older. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
References
# | Citation details | PMID |
---|---|---|
* | Government bodies | |
1. | European Medicines Agency (EMA). SmPC Nuvaxovid.
|
|
2. | Norwegian institute of public health. Vaccines and vaccination.
|
Tradenames